During the preceding titration phase, there were more additional follow-ups during semaglutide use because of several reasons, such as increased adverse events and the need for additional glycemic reviews for safety, although these additional follow-ups were predominantly accounted for by a minority of participants who were using open-loop pump therapy (Supplementary Table 3)
Patients should never attempt to self-administer unless trained by a qualified professional and provided with specific instructions from their compounding pharmacy or provider
Wegovy got FDA approval in 2021 specifically for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related health condition
Research indicates that patients relying on outdated treatments may experience unstable blood sugar levels and reduced effectiveness, ultimately requiring additional medical interventions that could have been avoided with proper management
Not everyone is eligiblebefore clearing you for a personalized GLP-1 Plan, our licensed Nurse Practitioner will assess your BMI to determine eligibility, as well as review your current health status
